Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae

H. Ikejima, H. Yamamoto, K. Ishida, Mitsuo Kaku, J. Shimada

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

We made a comparative study of the in-vitro activities of grepafloxacin (GPFX), ofloxacin (OFLX), erythromycin (EM), clarithromycin (CAM), roxithromycin (RXM), and minocycline (MINO) against 20 strains of Mycoplasma pneumoniae (17 clinical isolates and 3 standard strains). The minimum inhibitory concentration (MIC)90-to-minimum bactericidal concentration (MBC)90 ratio showed that the new quinolones have bactericidal effects on M. pneumoniae. Thus, it is expected that the new quinolones, especially grepafloxacin, will be clinically useful antimicrobial agents for the treatment of M. pneumoniae infection because of their good pharmacokinetic properties and bactericidal action.

Original languageEnglish
Pages (from-to)148-150
Number of pages3
JournalJournal of Infection and Chemotherapy
Volume6
Issue number3
DOIs
Publication statusPublished - 2000 Jan 1
Externally publishedYes

Keywords

  • Grepafloxacin (GPFX)
  • MIC
  • Mycoplasma pneumoniae

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae'. Together they form a unique fingerprint.

Cite this